Citation
- Authors: Rasoulouniriana D. et al.
- Year: 2019
- Journal: J Clin Invest 129 4151-4164
- Applications: in vitro / DNA / jetPRIME
- Cell types:
- Name: GP+E-86
- Name: HEK-293FT
Abstract
While a high frequency of Th1 cells in tumors is associated with improved cancer prognosis, this benefit has been attributed mainly to support of cytotoxic activity of CD8+ T cells. By attempting to potentiate antibody-driven immunity, we found a remarkable synergy between CD4+ T cells and tumor-binding antibodies. This surprising synergy was mediated by a small subset of tumor-infiltrating CD4+ T cells that express the high-affinity Fc